Trimetazidine as an Adjunct to Enhance Clopidogrel Response.

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

April 1, 2019

Study Completion Date

April 1, 2019

Conditions
Platelet Dysfunction Due to Drugs
Interventions
DRUG

Trimetazidine

Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties (6). It is presently clinically used throughout Europe and in \>80 countries worldwide. It is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several-not yet fully understood-mechanisms of action (7). The best-known mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) (7).

Trial Locations (1)

000000

The University of the West Indies, Saint Augustine

All Listed Sponsors
lead

The University of The West Indies

OTHER

NCT03603249 - Trimetazidine as an Adjunct to Enhance Clopidogrel Response. | Biotech Hunter | Biotech Hunter